TRULICITY (Eli Lilly Australia Pty Ltd)
Product name
TRULICITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 working days (255)
Active ingredients
dulaglutide
Registration type
EOI
Indication
Type 2 Diabetes Mellitus: reduction in risk of major adverse cardiovascular events
TRULICITY (solution for injection) is now also indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have:
- established cardiovascular disease or
- multiple cardiovascular risk factors.